
**Review**

Current research, diagnosis, and treatment of fragile X-associated tremor/ataxia syndrome

Zukhrofi Muzar, Reymundo Lozano*

UC Davis MIND Institute and Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA.

**Summary**

Fragile X-associated tremor/ataxia syndrome (FXTAS) is caused by a premutation CGG-repeat expansion in the 5'UTR of the fragile X mental retardation 1 (FMR1) gene. The classical clinical manifestations include tremor, cerebellar ataxia, cognitive decline and psychiatric disorders. Other less frequent features are peripheral neuropathy and autonomic dysfunction. Cognitive decline, a form of frontal subcortical dementia, memory loss and executive function deficits are also characteristics of this disorder. In this review, we present an expansion of recommendations for genetic testing for adults with suspected premutation disorders and provide an update of the clinical, radiological and molecular research of FXTAS, as well as the current research in the treatment for this intractable complex neurodegenerative genetic disorder.

**Keywords:** FXTAS, tremor/ataxia, premutation carrier, FMR1, FMR1 mRNA, FMPR, late-onset neurological disorder and neurodegenerative disorder

1. Introduction

The fragile X mental retardation 1 gene (FMR1) which causes fragile X syndrome if fully mutated (more than 200 CGG-repeats in the polymorphic region- 5'UTR), was discovered in 1991. This discovery led to the description of premutation carriers (individuals with smaller alleles, 55-200 CGG repeats) and was followed by a better understanding of the transition propensity, the expansion of the unstable allele of women with the premutation, and a better genetic counseling for risk of offspring with fragile X syndrome (the most common monogenetic form of autism and intellectual disability). Later on an intermediate allele was described (45-54 repeats) which has a variable risk for disorders that are associated with the premutation. Although before the discovery of the FMR1 gene, Cronister and colleagues (1) had reported a much higher incidence of early ovarian failure (before the age of 40 years) in females premutation carriers (PMC), PMC were generally seen as clinically unaffected (2-4). After the description of fragile X-associated primary ovarian insufficiency (FXPOI) in 1991 and FXTAS in 2001, there has been a general recognition that premutation alleles are associated with a wide range of clinical involvement. It is now widely recognized that PMC are at risk to develop a range of mild cognitive and behaviors problems during childhood and neurological, psychiatric and other immune-mediated disorders during adulthood (5). The prevalence of the FMR1 premutation has been described to be 1 in 113 to 259 females and 1 in 260 to 813 males in the general population (6-11). This suggests that about 1 in 3,000 men and about 1 in 6,000 women in the general population have fragile X-associated tremor/ataxia syndrome (FXTAS), which could be a common neurodegenerative disorder among the general population; however, more studies are necessary to define the incidence and prevalence of FXTAS. The clinical recommendations for testing of FMR1 mutation have been expanded after the description of premutation disorders and in this review we provide recommendations of offering testing for adults and will discuss the recent clinical, radiological, molecular and treatment research in FXTAS.

2. Clinical indications for FXS genetic testing in adults

The family history is crucial to determine whether
there is an X-linked inheritance pattern of intellectual disability (ID) which would be typical for fragile X syndrome. However clinical suspicion of a premutation disorder should also be a consideration for FMR1 DNA testing. The American Academy of Pediatrics and the American College of Medical Genetics currently recommends FMR1 DNA testing for all children and adults with undiagnosed developmental delay/ID (12) and/or autism (ASD) (13). The American College of Obstetricians and Gynecologist (ACOG) also recommends testing in women with a family history of fragile X-related disorders, such as, unexplained ID/developmental delay, ASD or primary ovarian insufficiency (POI). In order to expand the screening criteria and to capture more premutation carriers the ACOG also recommends offering testing to all women who request fragile X carrier screening regardless of their personal and family history and also recommends to offer prenatal testing by amniocentesis or CVS to a known pregnant PMC (14). We also recommend considering genetic testing when there is personal medical history of unexplained late onset dementia or parkinsonism with any other associated premutation disorder and to consider testing in individuals with family history of a member with unexplained POI and mood/anxiety disorder, fibromyalgia and mood/anxiety disorder, and undiagnosed dementia or parkinsonism and anxiety/mood disorder (Table 1).

3. FXTAS

Although the prevalence of FXTAS in the general population is uncertain, FXTAS occurs in approximately 40-45% of male PMC and 8-16% of female PMC over the age of 50 (15-18). The common features of FXTAS are cognitive decline, autonomic dysfunction, neuropathy, and psychiatric features such as anxiety, depression, and apathy (16,19-21). Impairments in executive function abilities including working memory, inhibitory control and visuospatial processing begin as early as middle adulthood, and progressively worsen with increasing age (22-26). Subsequently dementia develops in approximately 50% of male PMC and autonomic dysfunction which is thought to be a consequence of involvement of the peripheral nervous system in common (27,28). Premutation-associated psychiatric problems are common in adulthood but these problems can worsen before the appearance of tremor and ataxia (20,29-31). The increased lifetime prevalence of mood disorders (65%) and of anxiety disorders (52%) in individuals with FXTAS is greater than in those PMC without the FXTAS (20,31). The age of onset of FXTAS is typically between the ages of 60 and 65 years; the mean age of onset is 62 years (32,33). However, the chance of developing core symptoms of FXTAS (tremor and ataxia) increases with age. From age 50-59 the prevalence of FXTAS in males is 17 percent, from age 60-69 about 38 percent, from age 70-79 about 47 percent, and in males over 80 years old, about 75 percent (32).

Men are more frequently diagnosed with a definite diagnosis of FXTAS compared to women (34). A previous longitudinal study of progression of tremor and ataxia in 55 male PMCs showed that tremor usually occurs first, with median onset of ~ 60 years of age (35). After the tremor onset, the median onset of ataxia was 2 years later; onset of falls was 6 years later; dependence on a walking aid was 15 years later; and death was 21 years later (35). The rate of progression of FXTAS varies and life expectancy is between 5 to 25 years after the onset of the symptoms (36).

FXTAS in females was initially reported in 2004 (37). FXTAS is less common and shows a milder presentation in females because they have a normal X chromosome in addition to the FMR1-premuted X-chromosome (34). The proportion of normal FMR1 alleles on the active X chromosome (activation ratio) is thought to modulate the phenotypic severity in females (38); however, double heterozygous female have been reported and they seem to have a similar clinical presentation to heterozygous females (39,40). Dementia was found in 21-50% males with FXTAS (32,36). In females with FXTAS, however, dementia is far less common (36,37) and it has been reported in only a few cases (41-45). Females with FXTAS may also exhibit parkinsonism, although at a lower rate than in males with FXTAS (34). There are associated symptoms in females with FXTAS that usually do not occur in males, including thyroid disorders, fibromyalgia and chronic muscle pain (46,47). Conversion disorder has also been reported in a PMC female (48). Migraine headache were reported in a higher rate in females (54.2%) when

---

Table 1. Guidelines to recommend and offer FXS genetic testing

<table>
<thead>
<tr>
<th>Recommend Genetic Testing</th>
<th>Offer Genetics Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td>Family history of POI and mood/anxiety disorder</td>
</tr>
<tr>
<td>• Premature ovarian insufficiency</td>
<td>• Family history fibromyalgia and mood/anxiety disorder</td>
</tr>
<tr>
<td>• Women who request fragile X prenatal carrier screening</td>
<td>• Prenatal testing by amniocentesis or CVS for known PMC</td>
</tr>
<tr>
<td>All Adults</td>
<td>Late onset dementia associated other premutation disorders</td>
</tr>
<tr>
<td>• Intellectual Disability (ID)</td>
<td>• Family history of undiagnosed dementia or parkinsonism associated other premutation disorders</td>
</tr>
<tr>
<td>• Autism Spectrum Disorder (ASD)</td>
<td>&quot;MCP sign&quot; or white matter lesions in the cerebral white matter on MRI</td>
</tr>
<tr>
<td>• Family history of ID or ASD</td>
<td></td>
</tr>
<tr>
<td>• Family history of FXS</td>
<td></td>
</tr>
<tr>
<td>• Unexplained late onset tremor and ataxia</td>
<td></td>
</tr>
</tbody>
</table>

---
compared with males (26.8%) with the permutation (49). Immune mediated disorders have been described at a higher rate in females with FXTAS 72.73% compared with 46.54% female carriers and both rates are higher than published controls (47). Females with FXTAS also have a lower frequency of tremor compared to males with FXTAS (34).

4. Radiological findings

Cerebral magnetic resonance imaging (MRI) in patients with FXTAS shows global brain atrophy, enlargement of ventricular volume, white matter disease and heightened signal intensity with lesions in the middle cerebellar peduncles (50-53) (Figure 1). The middle cerebellar peduncle (MCP) sign presents as white matter hyperintensities in the middle cerebellar peduncles, and it is a cardinal radiological sign for the diagnosis of FXTAS (16). The MCP sign includes fronto-cerebellar tracts connecting to orbitofrontal and dorsolateral prefrontal cortices that are critical for cognitive control (54). Correspondingly, those with FXTAS and the MCP sign are likely to have more severe cognitive deficits and a longer history of symptoms than those without the MCP sign (55). Asymptomatic FMR1 premutation carriers show white matter alterations (demyelination and axonal damage) of the afferent projections of the MCPs and superior cerebellar peduncles (53,56,57), which may be the earliest neuroanatomical marker of the onset of cognitive and motor symptoms associated with FXTAS (58).

Other common neuroimaging signs of FXTAS include white matter hyperintensities in the pons, insula, splenium of the corpus callosum, and periventricular region (59,60). T2-weighted and FLAIR corpus callosum splenium (CCS) hyperintensity was as frequent (68%) as MCP hyperintensities (64%) and it may be a marker of severe disease progression in FXTAS (34). Women with FXTAS have less white matter disease and brain atrophy on MRI, as well as less dementia in late-stages of FXTAS than men with FXTAS (36,50). The MCP sign was demonstrated in 13% of females compared with 58% of males with FXTAS (50). Corpus Callosum Splenium (CCS) hyperintensities were present in 50% of females versus 72% males (34).

5. Diagnosis and clinical severity stage of FXTAS

The FXTAS diagnostic revised criteria are presented in Table 2 (16,17). The clinical severity of FXTAS is estimated by using an empirical staging system, which incorporates the motor signs of FXTAS. The system gives an indication of the impact of motor aspects of the disease on activities of daily living as described in Table 3.

6. Molecular mechanisms of FXTAS

PMC were initially described with normal FMRP levels (61-64). However new molecular techniques led Tassone and colleagues (2000) (65) to the identification of increased FMR1 mRNA levels; Kenneson and colleagues (2001) (66) also demonstrated low FMRP levels in PMC. Current research shows that as the premutation increases from 55 to 200, particularly

![Figure 1. MRI features of FXTAS. (A1) Moderately thin truncus of the corpus callosum with severe increased signal intensity in both the truncus and the splenium, and moderate cerebellar and cerebral (A2) volume loss. (A3) Mild white matter changes in the middle cerebellar peduncles (MCPs). (B1) Severe increased T2 signal intensity in the pons (can also be seen in B3). (B2) Severe diffuse increased T2 signal intensity in the deep white matter of the cerebrum, as well as periventricular. (B3) Moderately thin truncus of the corpus callosum with severe increased T2 signal intensity in both the truncus and the splenium.](image)

Table 2. Current diagnostic criteria of FXTAS

<table>
<thead>
<tr>
<th>Molecular: FMR1</th>
<th>Gray mutation, premutation or full mutation (Mandatory for all categories).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic</td>
<td>Definite: one major clinical + one major radiological or one major clinical + intranuclear inclusions (postmortem)</td>
</tr>
<tr>
<td></td>
<td>Probable: two major clinical or one minor clinical + one major radiological</td>
</tr>
<tr>
<td></td>
<td>Possible: one major clinical + one minor radiological</td>
</tr>
<tr>
<td>Clinical</td>
<td>Major: intention tremor; cerebellar ataxia</td>
</tr>
<tr>
<td></td>
<td>Minor: Parkinsonism; moderate to severe short term or executive function deficits; neuropathy</td>
</tr>
<tr>
<td>Radiological</td>
<td>Major: MCPs; MRI white matter lesions in splenium of the corpus callosum (or postmortem intranuclear inclusions)</td>
</tr>
<tr>
<td></td>
<td>Minor: MRI lesions in the cerebral white matter; moderate to severe generalized atrophy</td>
</tr>
</tbody>
</table>

MCPs; white matter lesions in middle cerebellar peduncle sign.
more than 110 CGG repeats, the level of FMR1 mRNA increases and the levels of FMRP start to decline (67,68). The CGG repeat size also correlates with the age of onset and the age of death from FXTAS (38,67). The elevated level of mRNA in PMCs led to the hypothesis of "FMR1 mRNA toxicity" in FXTAS, however the causative mechanism of increase transcription by the CGG repeat remains unclear as well as the mechanism of neuronal toxicity by the accumulation of the FMR1 mRNA. There are a few suggested pathological models including; "RNA toxicity"; a sequestration model which suggests that the RNA expanded CGG repeats are pathogenic by toxic sequestration of crucial transcriptional proteins (DROSHA-DGCR8, hnRNP A2/B1, SAM68, Purα, Rm62, and CUGBP1) (69-72); a non-canonical translation the CGG repeats which may result in the expression of toxic polyglycine products (73,74); and lastly the presence of antisense FMR1 transcription which may lead to toxicity by antisense transcripts products (75).

7. Neuropathology and neurobiology of FXTAS

The neuronal toxicity is thought to be led by the formation of pathognomonic eosinophilic and ubiquitin-positive intranuclear inclusions in neurons and astrocytes throughout the brain, peripheral nervous system and other organs such as the adrenals, thyroid, heart, Leydig cells and pancreas (28,76-78). Other findings include mild brain atrophy and involvement of the cerebellum (MPC sign), loss of Purkinje neuronal cells, spongiosis of the deep cerebellar white matter, Bergman gliosis, and swollen axons (51,77). Neurons of heterozygous female mice with the premutation showed shorter dendritic lengths and fewer branches between 7 and 21 days compared with wild-type (WT) littersmates, display lower viability, and express elevated stress protein levels (79). Furthermore altered embryonic neocortical development (80) and abnormal spontaneous clustered calcium bursts (81,82) with glutamate hyper-responsiveness have been described (81); thus suggesting a clear state of neuronal vulnerability.

Mitochondrial abnormalities have also been found in PMC (83,84) and recently a decreased immune responses and immune dysregulation in both humans and mice with the premutation were described (85). It is unknown how the premutation alters mitochondrial and immunological responses, and if these abnormalities contribute to FXTAS and other associations found in PMC, such as, autoimmune and rheumatologic disorders (47).

8. Treatment of FXTAS

There are as yet no effective targeted therapies for the treatment of FXTAS; however there are many medications that have been used to ameliorate some of the symptoms associated to FXTAS. However the use of these medications rely on very few small trials and case studies that showed improvements only in some individuals (86,87). The only clinical targeted trial for FXTAS utilized memantine (NMDA receptor antagonist, FDA approved for treatment of moderate to severe Alzheimer's disease since 2003). Memantine was thought to selectively block the excitotoxic effects associated with abnormal transmission of glutamate while allowing for the physiological transmission associated with normal cell functioning. In this randomized, double-blind, placebo-controlled trial, 94 individuals aged 34-80 years with probable or possible FXTAS diagnosis and clinical stages 1-5 were enrolled for one year. Primary outcome measures were the Behavioral Dyscontrol Scale (BDS) score and CATSYS intention tremor severity. Intention-to-treat analysis showed no improvement with respect to intention tremor severity nor BDS scores (88). However of those (94 participants) 41 completed longitudinal ERP studies (20 placebo/21 memantine group) and the use of this compound showed improvements on cued-recall memory and N400 repetition effect amplitude; thus suggest that the treatment may have benefits on verbal memory (88). More frequent mild adverse events were observed in the placebo group, while more frequent moderate adverse events occurred in the memantine group and these included dizziness, headache and constipation amongst others. As mention before other treatments are directed to symptom reduction. For anxiety and depression selective serotonin and selective norepinephrine reuptake inhibitors are effective (5,86) as well as psychotherapy (31). Atypical antipsychotics are effective in individuals with psychosis and agitation.

### Table 3. Clinical staging of FXTAS

<table>
<thead>
<tr>
<th>Stage</th>
<th>Clinical Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal functions</td>
</tr>
<tr>
<td>1</td>
<td>Subtle or questionable signs such as subtle tremor or mild balance problems and no interference with ADLs</td>
</tr>
<tr>
<td>2</td>
<td>Clear tremor and/or balance problems and minor interference with ADLs</td>
</tr>
<tr>
<td>3</td>
<td>Moderate tremor and/or balance problems and occasional falls and significant interference with ADLs</td>
</tr>
<tr>
<td>4</td>
<td>Severe tremor and/or balance problems with at least intermittent use of a cane or a walker</td>
</tr>
<tr>
<td>5</td>
<td>The use of a wheelchair on a daily basis</td>
</tr>
<tr>
<td>6</td>
<td>Bedridden</td>
</tr>
</tbody>
</table>

ADL: activities of daily living.
Propranolol and primidone may improve tremor (86,87,90). Deep brain stimulation has shown benefits for tremor and in few cases for ataxia (91); however the general outcome for FXTAS patients was poor (92). As previously mentioned the premutation causes neuronal susceptibility and therefore other treatments for PMC focus on preventive measures, such as, avoidance of toxins including smoking alcohol and some types of anesthetics, healthy diet and vitamins/antioxidants supplementation, exercise and cognitive training, and stress reduction (93).

9. Current research on FXTAS

Phenotype studies aim to determine early signs of disease for early diagnosis and treatment as well as to determine timing and reversibility of the pathological mechanism. A preliminary study shows that oculomotor inhibitory control impairments (measured by eye tracking) might precede FXTAS, and thus indicating elevated risk for motor impairment associated with FXTAS (94). Magnetic resonance imaging is useful for non-invasive testing; functional MRI for brain activation during cognitive tasks, and structural MRI for quantification of volume changes, morphometry, and white/gray matter integrity and connectivity. In fact, verbal working memory in male and female premutation carriers (95) has been associated with reduced activation in the right inferior frontal cortex and left premotor cortex in both asymptomatic premutation carriers and carriers with FXTAS. Reduced activation was found in right premotor/inferior frontal cortex in individuals with FXTAS. Individuals with FXTAS also showed diffuse gray matter loss most prominent in areas important for working memory, including prefrontal cortex, anterior cingulate cortex, and cerebellum (96). Molecular studies aim to determine the early molecular mechanisms that induce neurodegeneration including cellular stress and toxicity. The mechanism for inclusion formation and identification the intranuclear inclusions proteins are also a fertile area of research. Current targeted treatment research focuses on reversing the neurobiological abnormalities in FXTAS with pharmaceutical compounds (e.g. allopregnanolone) and other molecular mechanisms of disease modification (oligonucleotide-based therapies to reduce FMR1 mRNA) as well as designing a mechanism that will allow blood-brain cross-transportation of pharmacological compounds.

Animal models for the fragile X premutation have been developed to understand the molecular mechanism of FXTAS (97). Mice models have shown increased FMR1 mRNA levels, decreased FMRP levels and ubiquitin-positive intranuclear inclusions (98). In addition, mice models showed neurocognitive deficits in spatial and temporal memory processes, impaired motor performance, and anxiety traits (99). In order to determine timing and reversibility of disease and their associate molecular mechanism, a doxycycline-inducible premutation mouse has been created (R. Hukema, Abstracts of the 1st Premutation Meeting, Perugia, Italy, 2013). Animal models are crucial in the testing of preclinical therapies, for instance the acute administration of the neurosteroid allopregnanolone mitigated cluster burst firing in mouse hippocampal premutation-neurons and identified allopregnanolone as a potential targeted treatment for premutation disorders (100).

10. FXTAS

The identification of the FMR1 gene has led to characterization of risk alleles and recently there are a variety of disorders associated with the premutation in children and adults. Although FXTAS is described to occur in premutation carriers only, recent reports identified FXTAS in individuals with grey zone/intermediate alleles (101,102), as well as in individuals with unmethylated full-mutation alleles (103) and in a few patients with full-mutation/premutation mosaicism (104). These findings increase the number of patients that are at risk for FXTAS with elevated FMR1 mRNA besides only those with the premutation.

The description of FXTAS as an intractable disorder, has led to expansion of recommendations for genetic testing in adults which in turn have caused ethical concerns for the identification of individuals at risk of FXTAS. These is a concern especially in males with the suspicion of the premutation because males do not have increased risk of having children with fragile X syndrome, but have about a 40% chances to develop FXTAS, if they are determined to be premutation carriers. However, the documentation of the premutation is helpful for both males and females because these individuals can be treated for many of the childhood and adult problems related to the premutation such as anxiety, depression, ADHD, hypertension, hypothyroidism, fibromyalgia, sleep apnea, and can be counseled to avoid toxicity from the environment that has the potential to bring on FXTAS at an earlier age. The identification of radiological signs of FXTAS is used by clinicians to make a clinical diagnosis of FXTAS; however, the phenotypic variability and progression of FXTAS should be taken in consideration as many adults will not meet all clinical criteria until advanced age, particularly females. There are also radiological and clinical gender variations, while males are more prone to develop dementia, females are more likely to develop other autoimmune-related disorders. The phenotypic variability of the premutation is partially explain by CGG expansion size, FMR1 mRNA levels, decrease FMRP and mosaicism; however, other mechanisms are now being consider including protein synthesis alterations, non-AUG translation, and antisense transcription, as well as, additional
genomic variants and environmental exposures (5). Further genotype to phenotype studies are necessary to determine the relative contribution of these pathological processes in this complex disorder. Many FDA approved medications have shown to improve some of the symptoms of FXTAS; however there are limited clinical trials and none that can prove the efficacy of these treatments. It is crucial to undertake further clinical trials of drugs that anecdotally have shown positive results in individuals with FXTAS. There has been only one targeted clinical trial for FXTAS and there is an urgent need to identify more compounds that target the pathogenesis of FXTAS, which in theory may reverse, treat or prevent the development of FXTAS.

Acknowledgements

This work was supported by the National Institute on Aging of the National Institutes of Health (P30 AG043097) and NICHD diversity supplement (HD036071). RL and ZM declare no competing financial interests.

References


(Received October 21, 2014; Accepted November 30, 2014)